JPRN-UMIN000006370已完成2 期
Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Squamous Cell Lung Cancer - Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Squamous Cell Lung Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who have previously treated with chemotherapy containing amrubicin. 2) Patients with symptomatic brain metastasis. 3) Patients with massive uncontrolled pleural or pericardial effusion ,or ascites. 4) Patients with active severe infections 5) Patients with double cancer within 5 years. 6) Patients with active interstitial pneumonia recognized by chest X-ray. 7) Patients with serious drug allergic reactions. 8) Patients with active concomitant pregnancy. 9) Patients with cardiac infarction or necessary cardiac function abnormality of the treatment. 10) Patients who have previously treated with a cumulative daunorubicin dose > 25 mg/kg, doxorubicin >500 mg/m2, epirubicin >900mg/m2, pirarubicin > 950mg/m2. 11) Patients with active gastric or duodenal ulcer 12) Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
2 期
Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Non-Small Cell Lung Cancerung Squamous Cell CarcinomaJPRN-UMIN000004832First Department of Surgery, Hamamatsu University School of Medicine35
已完成
2 期
Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Squamous Cell Lung CancerSquamous Cell Lung CancerJPRN-UMIN000004235Society for the study of previously treated squamous cell lung cancer30
已完成
2 期
Phase II study of amrubicin for previously treated advanced non-small cell lung cancerRecurrent non-small cell lung cancerJPRN-UMIN000001751Gunma University Hospital35
未知
不适用
A phase II study of Amrubicin in patients with previously treated small cell lung cancersmall cell lung cancerJPRN-C000000141Kinki University School of Medicine30
已完成
2 期
Phase II study of weekly amrubicin in patients with refractory or relapsed non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000002570ational Hospital Organization Nagoya Medical Center43